Vor Biopharma
58 hedge funds and large institutions have $188M invested in Vor Biopharma in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 12 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.03% less ownership
Funds ownership: 4.18% → 4.15% (-0.03%)
5% less funds holding
Funds holding: 61 → 58 (-3)
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
48% less capital invested
Capital invested by funds: $362M → $188M (-$174M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$2.26M |
| 2 |
HF
HRT Financial
New York
|
+$359K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$278K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$274K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$213K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.48M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$734K |
| 3 |
BlackRock
New York
|
-$460K |
| 4 |
PL
Parkwood LLC
Cleveland,
Ohio
|
-$458K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$252K |
VOR Hedge Fund Activity: Q1 2022 in Review
58 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q1 2022, worth a combined $188M — down 48% from $362M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of VOR and 9 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 13 added.
The largest buyer was Paradigm Biocapital Advisors, adding an estimated $2.26M. The largest seller was Vanguard Group, cutting an estimated $2.48M.
- 58 institutional investors held Vor Biopharma (VOR) as of Q1 2022, down from 61 in Q4 2021.
- Funds reported $188M of Vor Biopharma stock for Q1 2022, down 48% quarter-over-quarter.
- 9 funds opened new Vor Biopharma positions in Q1 2022 and 12 closed out, a net change of -3 holders.
- The largest Vor Biopharma buyer in Q1 2022 was Paradigm Biocapital Advisors, an estimated $2.26M added.
- The largest Vor Biopharma seller in Q1 2022 was Vanguard Group, an estimated $2.48M sold.
Based on aggregated 13F filings for Q1 2022.